Last reviewed · How we verify
Ofatumumab 700 — Competitive Intelligence Brief
phase 2
Small molecule
Live · refreshed every 30 min
Target snapshot
Ofatumumab 700 (Ofatumumab 700) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Ofatumumab 700 TARGET | Ofatumumab 700 | GlaxoSmithKline | phase 2 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Ofatumumab 700 CI watch — RSS
- Ofatumumab 700 CI watch — Atom
- Ofatumumab 700 CI watch — JSON
- Ofatumumab 700 alone — RSS
Cite this brief
Drug Landscape (2026). Ofatumumab 700 — Competitive Intelligence Brief. https://druglandscape.com/ci/ofatumumab-700. Accessed 2026-05-15.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab